Bioactive Products
| A unique collection of 71 Anti-hyperlipidemic natural compounds with biological activity of Anti-hyperlipidemic | ||
| Catalog No: | Bb134 | Anti-hyperlipidemic Compound Library Screening Details |
| Size: | 1mg/well * 71 Compounds 2mg/well * 71 Compounds | |
| Cat. No. | Information |
| CFN98440 | Alpinumisoflavone Alpinumisoflavone has atheroprotective effects, may result from their ability to upregulate mechanisms promoting HDL-cholesterol and bile acid formation, it is endowed with estrogenic properties accounting, at least in part, for E. lysistemon effects. Alpinumisoflavone induces cell death, may be via repressing both the ERK/MAPK and NF-κB pathways. Alpinumisoflavone is active against both Gram-negative and Gram-positive bacteria, the minimum inhibitory concentration values obtained (MIC) ranged from 3.9 ug/mL to 125 ug/mL. |
| CFN98519 | Buddlejasaponin IV Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation. Buddlejasaponin IV exerts cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes, it may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat. |
| CFN98526 | Anhydroicaritin Anhydroicaritin exhibits immunosuppressive effects and has strong activity in scavenging DPPH radical. Anhydroicaritin can improve diet-induced obesity and hyperlipidemia and alleviate insulin resistance by suppressing SREBPs activation, it can serve as a leading compound for pharmacological control of metabolic diseases. Anhydroicaritin has the potential of stimulating the formation of mineralization nodules and further speeding up the formation of bone, it possesses significant protective effects on the zymosan-induced peritonitis mice, which may be associated with the regulation ofCa2+, influx in macrophages and iNOS expression. |
| CFN98493 | Jatrorrhizine Jatrorrhizine has neuroprotective, antioxidative, anti-inflammatory, antihypercholesterolemic, and anti-hyperglycemia effects.Jatrorrhizine is expected to be developed as a new gastric prokinetic drug, it is metabolized by human CYP1A2 and multiple UGT1A isoforms. It has inhibitory activities against the expression of inducible NO syntase (iNOS) and cyclooxygenase-2 (COX-2), and can improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1. |
| CFN98600 | Semialactone Semialactone shows inhibitory activities on human acyl-CoA:cholesterol acyltransferase(hACAT)1 with IC50 values of 79.1 uM and on human hACAT2 with IC50 values of 76.9 uM, it may be effective in the prevention and treatment of hypercholesterolemia or atherosclerosis via inhibitory effect on hACAT. |
